Dolutegravir

Jun 12, 2020

FDA Approves Drug to Treat Infants and Children with HIV

Jul 30, 2019

Five Years on, 3.9 Million People in the Developing World Have Access to HIV Treatment Dolutegravir, Thanks to Access-oriented Voluntary Licensing Agreements

Apr 08, 2019

FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment

May 02, 2018

The Medicines Patent Pool Adds New Suppliers from South Africa and South Korea to its Growing Generic Manufacturing Network

Nov 21, 2017

Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection

Nov 21, 2017

Janssen Announces U.S. FDA Approval of First and Only Complete, Single-Pill, Two-Drug Regimen, JULUCA® (Dolutegravir and Rilpivirine), for the Treatment of HIV-1 Infection

Nov 21, 2017

FDA approves first two-drug regimen for certain patients with HIV

Aug 07, 2017

Mylan Receives Tentative Approval for "TLD" Under PEPFAR

Jul 25, 2017

ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings

Jun 01, 2017

Janssen Announces Submissions in Europe and US for Single-Tablet Regimen of Dolutegravir plus Rilpivirine - the First Two-Drug HIV Maintenance Treatment